REG - GSK PLC - Latozinemab data read out

GSKAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2941Ea&default-theme=true

RNS Number : 2941E  GSK PLC  22 October 2025

Issued: 21 October 2025, London UK

 

GSK provides update on latozinemab

 

LONDON, 21 October 2025 -GSK plc (LSE/NYSE: GSK) and Alector, Inc. (Nasdaq:
ALEC) today confirmed headline results from the INFRONT-3 clinical trial
evaluating latozinemab in individuals with frontotemporal dementia due to a
mutation in the progranulin gene (FTD-GRN).

 

Although latozinemab treatment resulted in a statistically significant effect
on the INFRONT-3 biomarker co-primary endpoint of plasma progranulin (PGRN)
concentrations i  (#_edn1) , latozinemab did not show benefit on the clinical
co-primary endpoint of slowing FTD-GRN progression. The secondary and
exploratory endpoints also did not demonstrate treatment-related effects on
FTD-GRN. Preliminary safety data have not highlighted any major safety
concerns at present. More in-depth analysis of the data is ongoing.

Based on these results, the open-label extension portion of the INFRONT-3
trial and the continuation study for latozinemab will be discontinued.

Given the unmet medical need in neurodegeneration, innovation in this area is
still needed. GSK will evaluate the totality of these data to inform future
research.

 

The full results of the INFRONT-3 study will be presented at an upcoming
medical congress.

 

 

GSK and Alector Collaboration

In July 2021, GSK and Alector entered into a collaboration and license
agreement to collaborate on the global development and commercialization of
progranulin-elevating monoclonal antibodies, including latozinemab. Alector
led the global clinical development of latozinemab through Phase 2
proof-of-concept. Thereafter, Alector and GSK shared development
responsibilities and all costs for global development were divided between the
two companies.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Simon Steel        +44 (0) 20 8047 5502  (London)
                      Sarah Clements     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

References

i GSK data on file

(#_ednref1)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEDESFEISELS



            Copyright 2019 Regulatory News Service, all rights reserved